Combining ligand-based and structure-based drug design in the virtual screening arena

Bibliography

• GOLEBIOWSKI A, KLOPFENSTEIN SR, PORTLOCK DE: Lead compounds discovered from libraries: Part 2. Curr. Opin. Chem. Biol. (2003) 7:308-325.
   PubMed Web of Science ®Google Scholar
• HERTZBERG RP, POPE AJ: High-throughput screening: new technology for the 21st century. Curr. Opin. Chem. Biol. (2000) 4:445-451.
   PubMed Web of Science ®Google Scholar
• DI MASI JA: New drug innovation and pharmaceutical industry structure: trends in the output of pharmaceutical firms. Drug Inf. J. (2000) 34(4):1169-1194.
   Web of Science ®Google Scholar
• BEDDELL CR, GOODFORD PJ, NORRINGTON FE, WILKINSON S, WOOTTON R: Compound designed to fit a site of known structure in human haemoglobin. Br. J. Pharmacol. (1976) 57:201-209.
   PubMed Web of Science ®Google Scholar
• GOODFORD PJ: Drug design by the method of receptor fit. J. Med. Chem. (1984) 27:558-564.
   PubMedGoogle Scholar
• ROBERTS N, MARTIN J, KINCHINGTON D et al.: Rational design of peptide-based HIV proteinase inhibitors. Science (1990) 243:358-361.
   Google Scholar
• ERICKSON J, NEIDHART DJ, VANDRIE J et al.: Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. Science (1990) 249:527-533.
   PubMed Web of Science ®Google Scholar
• DORSEY BD, LEVIN RB, MCDANIEL SL et al.: L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor. J. Med. Chem. (1994) 37:3443-3451.
   PubMed Web of Science ®Google Scholar
• JAIN AN: Virtual screening in lead discovery and optimization. Curr. Opin. Drug Discov. Devel. (2004) 7:396-403.
   PubMed Web of Science ®Google Scholar
• STAHURA FL, BAJORATH J: New methodologies for ligand-based virtual screening. Curr. Pharm. Des. (2005) 11:1189-1202.
   PubMed Web of Science ®Google Scholar
• XUE L, BAJORATH J: Molecular descriptors in chemoinformatics, computational combinatorial chemistry, and virtual screening. Comb. Chem. High Throughput Screen. (2000) 3:363-372.
   PubMed Web of Science ®Google Scholar
• MASON JS, GOOD AC, MARTIN EJ: 3D pharmacophores in drug discovery. Curr. Pharm. Des. (2001) 7:567-597.
   PubMed Web of Science ®Google Scholar
• LANGER T, KROVAT EM: Chemical feature-based pharmacophores and virtual library screening for discovery of new leads. Curr. Opin. Drug Discov. Devel. (2003) 6:370-376.
   PubMed Web of Science ®Google Scholar
• POZZAN A: Molecular descriptors and methods for ligand based virtual high throughput screening in drug discovery. Curr. Pharm. Des. (2006) 12:2099-2110.
   PubMed Web of Science ®Google Scholar
• HOU TJ, XU XJ: Recent development and application of virtual screening in drug discovery: an overview. Curr. Pharm. Des. (2004) 10:1011-1033.
   PubMed Web of Science ®Google Scholar
• HANSH C, LEO A: Exploring QSAR. In: Fundamentals and Applications in Chemistry and Biology. Hansh C, Leo A (Eds), American Chemical Society. Washington, DC, USA (1995).
   Google Scholar
• BARBOSA F, HORVATH D: Molecular similarity and property similarity. Curr. Top. Med. Chem. (2004) 4:589-600.
   PubMed Web of Science ®Google Scholar
• HOU T, XU X: Recent development and application of virtual screening in drug discovery: an overview. Curr. Pharm. Des. (2004) 10:1011-1033.
   PubMed Web of Science ®Google Scholar
• WOLD S, SJOSTROM M, ERIKSSON L: Partial least squares projections to latent structures (PLS) in chemistry. In: The Encyclopaedia of Computational Chemistry. von Ragué Schleyer P (Ed.), Wiley & Sons, UK (1998):2006-2022.
   Google Scholar
• LEACH AR, GILLET VJ: An Introduction in Chemoinformatics. Leach AR, Gillet VJ (Eds), Kluwer Academic Publishers, The Netherlands (2003).
   Google Scholar
• ERIKKSON L, JOHANSSON E, KETTANEH-WOLD N, WOLD S: Multi and Megavariate Data Analysis – Principles and Applications. Erikkson L, Johansson E, Kettaneh-Wold N, Wold S (Eds), Umetrics Academy, Sweden (2001).
   Google Scholar
• CATANA C, GAO H, ORRENIUS C, STOUTEN P: Linear and nonlinear methods in modeling the aqueous solubility of organic compounds. J. Med. Chem. (2005) 45:170-176.
   Google Scholar
• ROCHE O, SCHNEIDER P, ZUEGGE J et al.: Development of a virtual screening method for identification of frequent hitters in compound libraries. J. Med. Chem. (2000) 45:137-142.
   Web of Science ®Google Scholar
• ZUEGGE J, FECHNER U, ROCHE O, PARRATT NJ, ENGKVIST O, SCHNEIDER G: A fast virtual screening filter for cytochrom450 3A4 inhibition liability of compound libraries. Quant. Struct. Act. Relat. (2002) 21:249-256.
   Google Scholar
• SEEL M, TURNER DB, WILLET P: Effect of parameter variation on the effectiveness of HQSAR analysis. Quant. Struct. Act. Relat. (1999) 18:245-252.
   Google Scholar
• ROCHE O, TRUBE G, ZUEGGE J, PFLIMLIN P, ALANINE A, SCHNEIDER G: A virtual screening method for prediction of the hERG potassium channel liability of compound libraries. ChemBioChem (2002) 3:455-459.
   PubMed Web of Science ®Google Scholar
• GREENE J, KAHN S, SAVOJ H, SPRAGUE P, TEIG S: Chemical function queries for 3D database search. J. Chem. Comput. Sci. (1994) 34:1297-1308.
   Google Scholar
• MCGREGOR MJ, MUSKAL SM: Pharmacophore fingerprinting. 1. Application to QSAR and focused library design. J. Chem. Comput. Sci. (1999) 39:569-574.
   PubMedGoogle Scholar
• LANGER T, KROVAT EM: Chemical feature-based pharmacophores and virtual library screening for discovery of new leads. Curr. Opin. Drug Discov. Devel. (2003) 6:370-376.
   PubMed Web of Science ®Google Scholar
• CATALYST is available from Accelrys, 9685 Scranton Road, San Diego, CA 92121, USA.
   Google Scholar
• DISCO is available from Tripos, Inc., St Louis, MO (USA).
   Google Scholar
• GASP is available from Tripos, Inc., St Louis, MO (USA).
   Google Scholar
• DIXON SL, SMONDYREV AM, RAO SN: PHASE: A novel approach to pharmacophore modeling and 3D database searching. Chem. Biol. Drug Des. (2006) 67:370-372.
   PubMed Web of Science ®Google Scholar
• PATEL Y, GILLET VJ, BRAVI G, LEACH AR: A comparison of the pharmacophore identification programs: Catalyst, DISCO and GASP. J. Comp. Aided Mol. Des. (2002) 16:653-681.
   PubMed Web of Science ®Google Scholar
• GUENER O, CLEMENT O, KUROGI Y: Pharmacophore modeling and three dimensional database searching for drug design using catalyst. Curr. Med. Chem. (2004) 11:2991-3005.
   PubMed Web of Science ®Google Scholar
• VAN DRIE JH: Pharmacophore discovery – lessons learned. Curr. Pharm. Des. (2003) 9:1649-1664.
   PubMed Web of Science ®Google Scholar
• DROR O, SHULMAN-PELEG A, NUSSINOV R, WOLFSON HJ: Predicting molecular interactions in silico: I. A guide to pharmacophore identification and its applications to drug design. Curr. Med. Chem. (2004) 11:71-90.
   PubMed Web of Science ®Google Scholar
• CRAMER RD, PATTERSON DE, BUNCE JD: Comparative Molecular Field Analysis (CoMFA) 1.Effects of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. (1988) 110:5959-5967.
   PubMed Web of Science ®Google Scholar
• KUBINI H: Comparative molecular field analysis (CoMFA). In: The Encyclopaedia of Computational Chemistry. von Ragué Schleyer P (Ed.), Wiley & Sons, UK (1998):448-460.
   Google Scholar
• KLEBE G, ABRAHAM U: On the prediction of binding properties of drug molecules by comparative molecular field analysis. J. Med. Chem. (1993) 36:70-80.
   PubMed Web of Science ®Google Scholar
• LEMMEN C, LENGAUER T, KLEBE G: FLEXS: a method for fast flexible ligand superimposition. J. Med. Chem. (1998) 41:4502-4520.
   PubMed Web of Science ®Google Scholar
• MOREAU G, BROTO P: The autocorrelation of a topological structure: a new molecular descriptor. Nouv. J. Chim. (1980) 4:359-360.
   Google Scholar
• PASTOR M, CRUCIANI G, MCLAY I, PICKETT S, CLEMENTI S: GRid-Independent Descriptors (GRIND): a novel class of alignment-independent three-dimentional molecular descriptors. J. Med. Chem. (2000) 43:3233-3243.
   PubMed Web of Science ®Google Scholar
• FONTAINE F, PASTOR M, SANZ F: Incorporating molecular shape into the alignment-free GRid-IndependentDescriptors. J. Med. Chem. (2004) 47:2805-2815.
   PubMed Web of Science ®Google Scholar
• GASTEIGER J, LI X, RUDOLPH C, SADOVSKI J, ZUPAN J: Representation of molecular electrostatic potential by topological feature maps. J. Am. Chem. Soc. (1994) 116:4608-4620.
   Web of Science ®Google Scholar
• WAGENER M, SADOVSKI J, GASTEIGER J: Autocorrelation of molecular surface properties for modeling corticosteroid binding globulin and cytosolic Ah receptor activity by neural networks. J. Am. Chem. Soc. (1995) 117:7769-7778.
   Web of Science ®Google Scholar
• BAUKNECHT H, ZELL A, BAYER H, LEVI P, SADOWSKI J, GASTEIGER J: Locating biologically active compounds in medium-sized heterogeneous datasets by topological autocorrelation vectors: dopamine and benzodiazepine agonists. J. Chem. Inf. Comput. Sci. (1996) 36:1205-1213.
   PubMedGoogle Scholar
• MORO S, BACILIERI M, FERRARI C, SPALLUTO G: Autocorrelation of molecular electrostatic potential surface properties combined with partial least squares analysis as alternative attractive tool to generate ligand-based 3D-QSARs. Curr. Drug. Disc. Tech. (2005) 2:13-21.
   PubMedGoogle Scholar
• MORO S, BACILIERI M, CACCIARI B, SPALLUTO G: Autocorrelation of molecular electrostatic potential surface properties combined with partial least squares analysis as new strategy for the prediction of the activity of human A(3) adenosine receptor antagonists. J. Med. Chem. (2005) 48:5698-5704.
   PubMed Web of Science ®Google Scholar
• ZUPAN J, GASTEIGER J: Neural Networks in Chemistry and Drug Design (2nd edn). Zupan J, Gasteiger J (Eds),Wiley-VCH, Weinheim, Germany (1999).
   Google Scholar
• GASTEIGER J, TECKENTRUP A, TERFLOTH L, SPYCHER S: Neural networks as data mining tools in drug design. J. Phys. Org. Chem. (2003) 16:232-245.
   Web of Science ®Google Scholar
• CZERMINSKI R, YARSI A, HARTSOUGH D: Use of Support Vector Machine in pattern classification: application to QSAR studies. Quant. Struct. Act. Relat. (2001) 20:227-240.
   Google Scholar
• NORINDER U: Support Vector Machine models in drug design: applications to drug transport processes and QSAR using simplex optimisations and variable selection. Neurocomputing (2003) 55:337-346.
   Web of Science ®Google Scholar
• WARMUTH M, LIAO J, RATSCH G, MATHIESON M, PUTTA S, LAMMEN C: Active learning with Support Vector Machines in the drug discovery process. J. Chem. Comput. Sci. (2003) 43:667-673.
   PubMedGoogle Scholar
• BYVATOV E, FECHNER U, SADOWSKY J, SCHNEIDER G: Comparison of Support Vector Machines and artificial neural network system for drug/non-drug classification. J. Chem. Inf. Comp. Sci. (2003) 43:1882-1889.
   PubMedGoogle Scholar
• GHOSE AK, CRIPPEN GM: Atomic physicochemical parameters for three-dimensional structure-directed quantitative structure-activity relationships. I. partition coefficients as a measure of hydrophobicity. J. Comput. Chem. (1986) 7:565-577.
   Web of Science ®Google Scholar
• GHOSE AK, CRIPPEN GM: Atomic physicochemical parameters for three-dimensional- structure-directed quantitative structure-activity relationships. 2. Modeling dispersive and hydrophobic interactions. J. Chem. Inf. Comput. Sci. (1987) 27:21-35.
   PubMedGoogle Scholar
• GHOSE AK, PRITCHETT A, CRIPPEN GM: Atomic physicochemical parameters for three-dimensional structure-directed quantitative structure-activity relationships. 3. Modeling hydrophobic interaction. J. Comput. Chem. (1988) 9:80-90.
   Web of Science ®Google Scholar
• SCHNEIDER G, NEIDHART W, GILLER T, SCHMID G: ‘Scaffold hopping’ by topological pharmacophore search: a contribution to virtual screening. Angew. Chem. Int. Ed. (1999) 38:2894-2895.
   PubMed Web of Science ®Google Scholar
• MOE (The Molecular Operating Environment) is available from Chemical Computing Group, Inc., 1010 Sherbrooke Street West, Suite 910, Montreal, Canada H3A 2R7.
   Google Scholar
• SADOWSKI J, KUBINYI H: A scoring scheme for discriminating between drugs and non-drugs. J. Med. Chem. (1998) 41:3325-3329.
   PubMed Web of Science ®Google Scholar
• AJAY A, WALTERS WP, MURCKO MA: Can we learn to distinguish between ‘drug-like’ and ‘nondrug-like’ molecules? J. Med. Chem. (1998) 41:3314-3324.
   PubMed Web of Science ®Google Scholar
• Comprehensive Medicinal Chemistry (CMC) and MACCS-II Drug Data Report (MDDR) are available from Molecular Design Limited: San Leandro, CA (USA).
   Google Scholar
• Available Chemicals Directory (ACD) is available from Molecular Design Limited: San Leandro, CA (USA).
   Google Scholar
• SCAPIN G: Structural biology and drug discovery. Curr. Pharm. Des. (2006) 12:2087-2097.
   PubMed Web of Science ®Google Scholar
• BREDEL M, JACOBY E: Chemogenomics: an emerging strategy for rapid target and drug discovery. Nat. Rev. Genet. (2004) 5:262-275.
   PubMed Web of Science ®Google Scholar
• ABOLA E, KUHN P, EARNEST T, STEVENS RC: Automation of X-ray crystallography. Nat. Struct. Biol. (2000) 7:983-977.
   Google Scholar
• KUHN P, WILSON K, PATCH MG, STEVENS RC: The genesis of high-throughput structure-based drug discovery using protein crystallography. Curr. Opin. Struct. Biol. (2002) 6:704-710.
   Web of Science ®Google Scholar
• STOUT TJ, FOSTER PG, MATTHEWS DJ: High-throughput structural biology in drug discovery: protein kinases. Curr. Pharm. Des. (2004) 10:1069-1082.
   PubMed Web of Science ®Google Scholar
• TICKLE I, SHARFF A, VINKOVIC M, YON J, JHOTI H: High-throughput protein crystallography and drug discovery. Chem. Soc. Rev. (2004) 33:558-565.
   PubMed Web of Science ®Google Scholar
• ANDERSON AC: The process of structure-based drug design. Chem. Biol. (2003) 10:787-797.
   PubMed Web of Science ®Google Scholar
• KITCHEN DB, DECORNEZ H, FURR JR, BAJORATH J: Docking and scoring in virtual screening for drug discovery: methods and applications. Nat. Rev. Drug Discov. (2004) 3:935-949.
   PubMed Web of Science ®Google Scholar
• HONMA T, HAYASHI K, AOYAMA T et al.: Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. J. Med. Chem. (2001) 44:4615-4627.
   PubMed Web of Science ®Google Scholar
• JI H, ZHANG W, ZHANG M et al.: Structure-based de novo design, synthesis, and biological evaluation of non-azole inhibitors specific for lanosterol 14alpha-demethylase of fungi. J. Med. Chem. (2003) 46:474-485.
   PubMed Web of Science ®Google Scholar
• BOEHM HJ, BOEHRINGER M, BUR D et al.: Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. J. Med. Chem. (2000) 43:2664-2674.
   PubMed Web of Science ®Google Scholar
• LIEBESCHUETZ JW, JONES SD, MORGAN PJ et al.: PRO_SELECT: combining structure-based drug design and array-based chemistry for rapid lead discovery. 2. The development of a series of highly potent and selective Factor Xa inhibitors. J. Med. Chem. (2002) 45:1221-1232.
   PubMed Web of Science ®Google Scholar
• TAN C, WEI L, OTTENSMEYER FP et al.: Structure-based de novo design of ligands using a three-dimensional model of the insulin receptor. Bioorg. Med. Chem. Lett. (2004) 14:1407-1410.
   PubMed Web of Science ®Google Scholar
• SCHMIDT JM, MERCURE J, TREMBLAY GB, PAGE M, KALBAKJI A, FEHER M: De novo design, synthesis, and evaluation of novel nonsteroidal phenanthrene ligands for the estrogen receptor. J. Med. Chem. (2003) 46:1408-1418.
   PubMed Web of Science ®Google Scholar
• PIERCE AC, RAO G, BEMIS GW: BREED: Generating novel inhibitors through hybridization of known ligands. Application to CDK2, P38, and HIV protease. J. Med. Chem. (2004) 47:2768-2775.
   PubMed Web of Science ®Google Scholar
• MURCKO M: Recent advances in ligand design methods. In: Reviews in Computational Chemistry. Lipkowitz KB, Boyd DB (Eds), Wiley-VCH, New York, USA (1997):1-66.
   Google Scholar
• SCHNEIDER G, FECHNER U: Computer-based de novo design of drug-like molecules. Nat. Rev. Drug Discov. (2005) 4:649-663.
   PubMed Web of Science ®Google Scholar
• LLOYD DG, BUENEMANN CL, TODOROV NP, MANALLACK DT, DEAN PM: Scaffold hopping in de novo design. Ligand generation in the absence of receptor information. J. Med. Chem. (2004) 47:493-496.
   PubMed Web of Science ®Google Scholar
• COLE JC, MURRAY CW, NISSINK JW, TAYLOR RD, TAYLOR R: Comparing protein-ligand docking programs is difficult. Proteins (2005) 60:325-332.
   PubMed Web of Science ®Google Scholar
• LEACH AR, SHOICHET BK, PEISHOFF CE: Prediction of protein-ligand interaction. Docking and scoring: successes and gaps. J. Med. Chem. (2006) 49:5851-5855.
   PubMed Web of Science ®Google Scholar
• SOUSA SF, FERNANDES PA, RAMOS MJ: Protein-ligand docking: current status and future challenges. Proteins (2006) 65:15-26.
   PubMed Web of Science ®Google Scholar
• YANG JM, CHEN YF, SHEN TW, KRISTAL BS, HSU DF: Consensus scoring criteria for improving enrichment in virtual screening. J. Chem. Inf. Model. (2005) 45:1134-1146.
   PubMed Web of Science ®Google Scholar
• RODINGER T, POMES R: Enhancing the accuracy, the efficiency and the scope of free energy simulations. Curr. Opin. Struct. Biol. (2005) 15:164-170.
   PubMed Web of Science ®Google Scholar
• AJAY WP, MURCKO MA: Can we learn to distinguish between ‘drug-like’ and ‘non drug-like’ molecules? J. Med. Chem. (1998) 41:3314-3324.
   PubMed Web of Science ®Google Scholar
• LIPINSKI CA, LOMBARDO F, DOMINY BW, FEENEY PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. (1997) 23:3-25.
   Web of Science ®Google Scholar
• MATTER H, BARINGHAUS KH, NAUMANN T, KLABUNDE T, PIRARD B: Computational approaches towards the rational design of drug-like compound libraries. Comb. Chem. High Throughput Screen. (2001) 4:453-475.
   PubMed Web of Science ®Google Scholar
• HERT J, WILLETT P, WILTON DJ: New methods for ligand-based virtual screening: use of data fusion and machine learning to enhance the effectiveness of similarity searching. J. Chem. Inf. Model. (2006) 46:462-470.
   PubMed Web of Science ®Google Scholar
• LIPINSKI C, HOPKINS A: Navigating chemical space for biology and medicine. Nature (2004) 432:855-861.
   PubMed Web of Science ®Google Scholar
• CHEN YZ, ZHI DG: Ligand-protein inverse docking and its potential use in the computer search of protein targets of a small molecule. Proteins (2001) 43:217-226.
   PubMed Web of Science ®Google Scholar
• HINDLE SA, RAREY M, BUNING C, LENGAUER T: Flexible docking under pharmacophore type constrains. J. Comput. Aided Mol. Des. (2002) 16:129-149.
   Web of Science ®Google Scholar
• GOTO J, KATAOKA R, HIRAYAMA N: Ph4DOCK: Pharamcophore-based protein-ligand docking. J. Med. Chem. (2004) 47:6804-6811.
   PubMed Web of Science ®Google Scholar
• MOITESSIER N, HENRY C, MAIGRET B, CHAPLEUR Y: Combining pharmacophore search, automated docking and molecular dynamics simulations as a novel strategy fro flexible docking. Proof of concept: docking of arginine-glycine-aspartatic acid-like compounds into the avb3 binding site. J. Med. Chem. (2004) 47:4178-4187.
   PubMed Web of Science ®Google Scholar
• SIPPL W, HOLTJE HD: Structure-based 3D-QSAR-merging the accuracy of structure-based alignments with the computational efficiently of ligand-based methods. Teochem (2000) 503:31-50.
   Web of Science ®Google Scholar
• SIPPL W: Binding affinity prediction of novel estrogen receptor ligands using receptor-based 3D-QSAR methods. Bioorg. Med. Chem. (2002) 10:3741-3755.
   PubMed Web of Science ®Google Scholar
• BRIGO A, MUSTATA GI, BRIGGS JM, MORO S: Discovery of HIV-1 integrase inhibitors through a novel combination of ligand and structure-based drug design. Med. Chem. (2005) 1:263-275.
   PubMedGoogle Scholar
• MORO S, BRAIUCA P, DEFLORIAN F et al.: Combined target-based and ligand-based drug design approach as a tool to define 3D-pharmacophore model of human A3 adenosine receptor antagonists: pyrazolo [4,3-e] 1,2,4-triazolo[1,5-c]pyrimidine derivatives as a key study. J. Med. Chem. (2005) 48:152-162.
   PubMed Web of Science ®Google Scholar
• MORO S, DEFLORIAN F, BACILIERI M, SPALLUTO G: Novel strategies for the design of new potent and selective human A3 adenosine receptor antagonists: an update. Curr. Med. Chem. (2006) 13:763-771.
   Google Scholar
• TSAI KC, CHEN SY, LIANG PH et al.: Discovery of a novel family of SARS-Co protease inhibitors by virtual screening and 3D-QSAR studies. J. Med. Chem. (2006) 49:3485-3495.
   PubMed Web of Science ®Google Scholar
• MORO S, DEFLORIAN F, BACILIERI M, SPALLUTO G: G-protein-coupled receptors as challenging druggable targets: insights from in silico studies. New J. Chem. (2006) 30:301-308.
   Web of Science ®Google Scholar